Clinically, based on the state of hormone receptors (estrogen receptor [ER] and progesterone receptor [PR]), human epidermal growth factor receptor-2 (HER2), and Ki67 proliferation index, breast cancer is categorized into different molecular subtypes that have distinct risk profiles and treatment schemas (2, 3). Here, ERBB2 is linked to breast carcinoma.